NNC 0756 (odapipam)

Subscribe to Selected New Research on NNC 0756

8 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: structure given in first source; NNC 0756 is the (acetate,(+))-isomer and NNC 0772 is the (HCl,(-))-isomer; NNC 0756 is a potent dopamine D-1 receptor antagonist; odapipam is the (S)-isomer

Also Known As:

odapipam; 8-chloro-7-hydroxy-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; NNC 0756, (R)-isomer; NNC 0756, (S)-isomer; NNC 0756, (S)-isomer,C11-labeled; NNC 0772; NNC 756; NNC-0756; NNC-0772; NNC-756; 1H-3-Benzazepin-7-ol, 8-chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-, (S)-, acetate (salt)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Furans: 33

Benzofurans: 6

NNC 0756: 8

2-Ring Heterocyclic Compounds

Related Diseases

1.	Schizophrenia (Dementia Praecox) 08/14/1992 - "Thus, NNC-112, NNC-687 and NNC-756 are potent and selective dopamine D1 receptor antagonists that may be useful in the treatment of schizophrenia." Order ALL the reference details at left...
2.	Narcolepsy 12/01/1996 - "The caudate-to-cerebellum and putamen-to-cerebellum ratios of [11C]NNC 756 were within normal limits in patients with narcolepsy" 12/01/1996 - "Striatal dopamine D1 receptors in narcolepsy: a PET study with [11C]NNC 756." 12/01/1996 - "We investigated dopamine D1 receptors in the putamen and caudate nucleus with positron emission tomography in six patients with narcolepsy and five healthy controls using [11C]NNC 756 as ligand" Order ALL the reference details at left...
3.	Movement Disorders (Movement Disorder) 12/01/1995 - "SKF 81297, 0.3 mg/kg, induced acute oral dyskinesia and grooming, which were each inhibited by the DA D1 receptor antagonist NNC 756 in a dose-dependent manner" 10/01/2001 - "RESULTS: SKF 83959 acted as a DA D1 agonist (induced oral dyskinesia given alone, counteracted DA D1 antagonist [NNC 756], induced dystonia, and did not inhibit AMP induced behaviors)" 04/01/1994 - "No significant dyskinesia was induced by NNC 756, while raclopride significantly induced both acute and tardive oral dyskinesia" Order ALL the reference details at left...
4.	Dystonia (Limb Dystonia) 04/01/1994 - "NNC 756 induced no dystonia, while marked dystonia was induced by raclopride" 10/01/2001 - "RESULTS: SKF 83959 acted as a DA D1 agonist (induced oral dyskinesia given alone, counteracted DA D1 antagonist [NNC 756], induced dystonia, and did not inhibit AMP induced behaviors)" 11/01/1998 - "NNC 756 (0.004 and 0.01 mg/kg), raclopride (0.004 and 0.01 mg/kg), SKF 81297 (0.3 and 0.6 mg/kg), quinpirole (0.1 and 0.2 mg/kg), amphetamine (0.25 and 0.5 mg/kg), and biperiden (0.125 and up to 1.0 mg/kg), had no significant effect on MK-801-induced dystonia" 11/01/1998 - "MK-801 (dizocilpine), a noncompetitive N-methyl-D-aspartate antagonist, induces dystonia in monkeys at doses of 0.08 mg/kg. This syndrome was tested with the dopamine D1 receptor antagonist NNC 756, the DA D2 receptor antagonist raclopride, the atypical antipsychotic clozapine, the dopamine D1 receptor agonist SKF 81297, the dopamine D2/D3 receptor agonist quinpirole, the anticholinergic biperiden, amphetamine, and the benzodiazepine midazolam in 7 Cebus apella monkeys previously treated with dopaminergic agents" Order ALL the reference details at left...
5.	Dyskinesias (Dyskinesia) 04/01/1994 - "Concomitant treatment with NNC 756 tended to reduce the D1 agonist SKF 81297-induced dyskinesia and grooming, while concomitant treatment with raclopride increased SKF 81297-induced dyskinesia and tended to decrease SKF 81297-induced grooming" 04/01/1994 - "No significant dyskinesia was induced by NNC 756, while raclopride significantly induced both acute and tardive oral dyskinesia" 10/01/2001 - "SKF 83822, unlike previously studied DA D1 agonists, did not induce dyskinesia, but resulted in a state of extreme arousal and locomotor activation without stereotypy, effectively counteracted by NNC 756, but not by SKF 83959 nor raclopride (DA D2 antagonist).CONCLUSIONS: It is hypothesized that: 1) dyskinesia is linked to PLC stimulation; 2) DA D1 agonism can play a role in the induction of psychosis, via a mechanism linked neither to AC nor PLC, and 3) DA D1 antagonists differ in antipsychotic potential, possibly via this unidentified mechanism." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Dopamine D1 Receptors (Dopamine D1 Receptor)
2.	NNC 112
3.	5- (2,3- dihydrobenzofuran- 7- yl)- 3- methyl- 8- nitro- 2,3,4,5- tetrahydro- 1H- 3- benzazepin- 7- ol
4.	Raclopride
5.	Dopamine (Intropin)
6.	SK&F 81297
7.	Quinpirole
8.	Dopamine D2 Receptors (Dopamine D2 Receptor)
9.	Dizocilpine Maleate (Dizocilpine)
10.	N-Methylaspartate (NMDA)

Best Treatments:
Research Summary Report
on Schizophrenia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1311 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>